An Observational Study of Type 2 Diabetes in Patients Starting on NovoMix® 30 Treatment

• Status: Completed
• Trial end date: 2008-09-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is conducted in Europe. The aim of this observational study is to evaluate the incidence of serious adverse drug reactions when initiating or switching to insulin therapy with NovoMix® 30 in subjects with type 2 diabetes under normal clinical practice conditions

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novo Nordisk A/S
• Treatments: Biphasic Insulins; Insulin; Insulin Aspart; Insulin aspart, insulin aspart protamine drug combination 30:70; Insulin, Isophane

Criteria

Inclusion Criteria:

• Patients with Type 2 diabetes

• Insulin-naive or previously treated by basal only insulin therapy

Exclusion Criteria:

• Patients who are unlikely to comply with the protocol

• Pregnancy or breastfeeding or intention of becoming pregnant